Heat Biologics (HTBX) announced formation of it’s COVID-19 Advisory Board
Heat Biologics Inc (HTBX) currently trades at $0.55 and has fallen by 3.54% today. Heat announced today the formation of its COVID-19 Advisory Board (CAB) with four key appointments: Justin Stebbing MD, PhD, Raymond Pickles, PhD, Natasa Strbo MD, DSc, and Lanying Du, PhD. Heat’s COVID-19 Advisory Board was established with leading thought leaders to propel Heat’s COVID-19 vaccine and COVID-19 diagnostic programs.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating because the combined Advisory Board has expertise in areas of coronavirus and related respiratory virus biology and infection, immunotherapy, and vaccines. Heat recently announced a research collaboration with the University of Miami Miller School of Medicine to develop a vaccine leveraging Heat’s proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19. The high forecast for Heat Biologics Inc is $5.00 and the low is $2.00. Notably, the company’s market cap is $43.65 million with a 52 week high of $1.27 and a 52 week low of $0.20.